Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 12(64), 2020

DOI: 10.1128/aac.00807-20

Links

Tools

Export citation

Search in Google Scholar

Gallic and Ellagic Acids Are Promising Adjuvants to Conventional Amphotericin B for the Treatment of Cutaneous Leishmaniasis

Journal article published in 2020 by Michel Muálem de Moraes Alves ORCID, Daniel Dias Rufino Arcanjo ORCID, Kayo Alves Figueiredo, Jéssica Sara de Sousa Macêdo Oliveira, Felipe José Costa Viana, Elvilene de Sousa Coelho, Glaucia Lais Nunes Lopes, Juan Carlos Ramos Gonçalves ORCID, André Luís Menezes Carvalho, Márcia dos Santos Rizzo ORCID, Mariana Helena Chaves, Ivete Lopes de Mendonça, Fernando Aécio de Amorim Carvalho
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

In this study, we demonstrated the potential associative effect of combining conventional amphotericin B (Amph B) with gallic acid (GA) and with ellagic acid (EA) in topical formulations for the treatment of cutaneous leishmaniasis in BALB/c mice. Preliminary stability tests of the formulations and in vitro drug release studies with Amph B, GA, Amph B plus GA, EA, and Amph B plus EA were carried out, as well as assessment of the in vivo treatment of BALB/c mice infected with Leishmania major .